Clinical Trial Update: TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating potential drug-drug interaction between rilpivirine (TMC278) 25 mg daily and methadone at steady state in HIV-infected participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)
• Methadone (methadone)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV | Phase 1 | Status: COMPLETED